Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences (ASMB) has 9 years of Non-Current Deffered Revenue data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 94.72% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, down 94.72%, while the annual FY2024 figure was $35.4 million, 36.12% down from the prior year.
  • Non-Current Deffered Revenue reached $1.7 million in Q3 2025 per ASMB's latest filing, down from $13.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $55.4 million in Q4 2023 and bottomed at $1.7 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $13.9 million, with a median of $2.7 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 1926.31% in 2023, then plummeted 94.72% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then surged by 1926.31% to $55.4 million in 2023, then tumbled by 36.12% to $35.4 million in 2024, then tumbled by 95.15% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $1.7 million in Q3 2025, $13.0 million in Q2 2025, and $22.8 million in Q1 2025.